(101 days)
Not Found
No
The device description and performance studies focus on a traditional ELISA assay kit and its analytical performance, with no mention of AI or ML components.
No
The device is an in-vitro diagnostic (IVD) test system intended for quantitative measurement of free testosterone in human serum, which is used in the diagnosis and treatment of disorders. It does not directly treat or prevent a disease or condition.
Yes
The "Intended Use / Indications for Use" section explicitly states that the measurement of free testosterone using this system is "used in the diagnosis and treatment of disorders." This directly indicates its role as a diagnostic device.
No
The device description clearly outlines a physical kit containing vials of reagents, a microplate, and solutions, which are hardware components.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative measurement of free testosterone in human serum." This is a measurement performed in vitro (outside the body) on a biological sample (serum) to provide information for the "diagnosis and treatment of disorders." This directly aligns with the definition of an IVD.
- Device Description: The description details a kit containing reagents, calibrators, controls, and a microplate designed for performing an Enzyme Immunoassay (EIA) on a serum sample. This is a typical format for an IVD test kit.
- Performance Studies: The document describes analytical performance studies (precision, linearity, recovery, stability, detection limits, cross reactivity) and method comparison studies, which are standard evaluations for IVD devices to demonstrate their analytical and clinical performance.
- Predicate Device: The mention of a predicate device (K030730; EiAsy Free Testosterone EIA) indicates that this device is being compared to a previously cleared IVD, which is a common regulatory pathway for new IVD submissions.
All these elements strongly indicate that the Free Testosterone AccuBind® ELISA Test System is an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Free Testosterone AccuBind® ELISA Test System is an Enzyme Immunoassay (EIA) for the quantitative measurement of free testosterone in human serum. Measurement of free testosterone is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, impotence in males and in females; hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries and adrogenital syndromes.
Product codes
CDZ
Device Description
Monobind Inc. Free Testosterone test system uses a competitive enzyme immunoassay. The essential reagents required for a solid phase enzyme immunoassay include immobilized antibody, enzyme-antigen conjugate and native antigen. Upon mixing immobilized antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of insolubilized binding sites. After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an be ascertained. The serum calibrators are prepared in human serum matrix. The enzyme-antigen conjugate is labelled with horseradish peroxidase (HRP) and the substrate reagent contains tetramethylbenzidine (TMB), a blue color is produced. The reaction is stopped with addition of an acid and a yellow color is developed. The plate is read in a microtiter plate reader at 450nm.
The kit consists of seven (7) vials of serum reference calibrators for Free Testosterone with two (2) controls (one low and one high); one (1) vial of Testosterone (Analog)-horseradish peroxidase (HRP) conjugate in a protein stabilizing matrix; one 96-well testosterone antibody-coated microplate; one (1) vial of concentrated wash solution; two (2) vials for tetramethy(benzidine (TMB) substrate solution preparation; and one (1) vial of stop reaction solution.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
-
Analytical Performance - Precision:
- Study Type: Precision study
- Sample Size: 80 measurements per sample (human serum and control samples tested in duplicate, two times per day for 20 days)
- Key Results: Precision data reported as SD and CV% for within-run, within-kit, and total precision for control and patient samples at various concentrations.
- Control 1 (2.48 pg/ml): Total Precision SD 0.21, CV 8.51%
- Control 2 (11.04 pg/ml): Total Precision SD 0.87, CV 8.00%
- Control 3 (23.24 pg/ml): Total Precision SD 1.83, CV 7.95%
- Patient 1 (0.97 pg/ml): Total Precision SD 0.08, CV 9.43%
- Patient 2 (4.62 pg/ml): Total Precision SD 0.33, CV 7.20%
- Patient 3 (54.66 pg/ml): Total Precision SD 4.13, CV 7.55%
-
Analytical Performance - Linearity:
- Study Type: Linearity study per CLSI EP06-A guidance
- Sample Size: 11 concentrations (0.10-64.91 pg/mL)
- Key Results: Linear regression obtained: y=1.0149x-0.6028, R =0.9888.
-
Analytical Performance - Recovery:
- Study Type: Recovery study
- Sample Size: Five serum samples with different endogenous testosterone levels.
- Key Results: Average % recovery ranged from 98.7% to 105.2%.
-
Analytical Performance - Reagent Stability/Sample Stability:
- Study Type: Real-time stability studies
- Key Results:
- Long-term stability for kit reagents stored at 2-8℃ is 2 years.
- Open Kit/Calibrators/Controls/Enzyme Reagent/TMB Substrate/Antibody Coated Plate stability: 61 days at 2-8℃.
- Serum Sample stability: 61 days at 2-8℃.
- Frozen Serum Sample stability: 31 days at -20℃.
-
Analytical Performance - Expected Reference Values:
- Study Type: Reference range establishment and verification
- Sample Size: 261 male and female serum samples
- Key Results: Reference ranges provided for different age groups in males and females.
-
Analytical Performance - Detection Limits:
- Study Type: Determination of LOB, LOD, and LOQ in accordance with CLSI EP 17-A guideline.
- Key Results:
- Limit of the Blank (LoB): 0.0295pg/ml
- Limit of Detection (LoD): 0.0519pg/ml
- Limit of Quantitation (LoQ): 0.0519pg/ml
-
Analytical Performance - Cross Reactivity:
- Study Type: Cross-reactivity study in accordance with CLSI EP07-A2.
- Key Results: Various compounds tested for cross-reactivity. Significant cross-reactivity defined as > 10% difference. Most compounds showed 0.000% cross-reactivity.
- 11-KetoTestosterone: Male Serum 0.647%, Blank Serum 0.519%
- 11β-Hydroxytestosterone: Male Serum 0.065%, Blank Serum 0.054%
- 5a-Dihydrotestosterone: Male Serum 0.054%, Blank Serum 0.042%
- Andronstenedione: Male Serum 0.004%, Blank Serum 0.002%
- Epistestosterone: Male Serum 0.001%, Blank Serum 0.001%
- Testosterone SO4: Male Serum 0.004%, Blank Serum 0.003%
- Testosterone Cypionate: 0.002%
- Testosterone Undecanoate: -0.001%
-
Method Comparison Studies:
- Study Type: Comparison between new device and predicate assay (EiAsy Free Testosterone EIA).
- Sample Size: 137 samples
- Key Results: Least Square Regression Analysis: y= 1.017x - 0.244, Correlation Coefficient: 0.997.
-
Interferences:
- Study Type: Interference testing per CLSI-A2.
- Key Results: No significant interference observed for various substances at specified concentrations.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Key metrics mentioned are precision (SD, CV%), recovery (%), linearity (R), detection limits (LoB, LoD, LoQ), and cross-reactivity (%). For method comparison, correlation coefficient and regression equation are provided.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1680 Testosterone test system.
(a)
Identification. A testosterone test system is a device intended to measure testosterone (a male sex hormone) in serum, plasma, and urine. Measurement of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.(b)
Classification. Class I.
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
July 20, 2018
Monobind Inc. Anthony Shatola Quality Director 100 North Pointe Drive Lake Forest, CA 92630
Re: K181017
Trade/Device Name: Free Testosterone AccuBind ELISA Test System Regulation Number: 21 CFR 862.1680 Regulation Name: Testosterone test system Regulatory Class: Class I, reserved Product Code: CDZ Dated: June 18, 2018 Received: June 19, 2018
Dear Anthony Shatola:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR
1
Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K181017
Device Name
Free Testosterone AccuBind® ELISA Test System
Indications for Use (Describe)
The Free Testosterone AccuBind® ELISA Test System is an Enzyme Immunoassay (EIA) for the quantitative measurement of free testosterone in human serum. Measurement of free testosterone is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, impotence in males and in females; hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries and adrogenital syndromes.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
B Monobind Inc.
The World Resource for Diagnostic Products
510(k)Summarv
| 1. | Submitted by: | Monobind Inc. |
|---|---|---|
| Address: | 100 North Pointe Drive | |
| Lake Forest, CA 92630, USA | ||
| Phone: | 949-951-2665 | |
| Fax: | 949-951-3539 | |
| Website: | www.monobind.com | |
| CompanyContact: | Anthony Shatola, Quality Director | |
| Date: | July 12, 2018 | |
| 2. | Product Trade Name: | Free Testosterone AccuBind® ELISA Test system |
| FDA Submission Number: | K181017 | |
| Classification Name: | Radioimmunoassay,testosterone and dihydrotestosterone | |
| ProductCode: | CDZ | |
| Classification: | Class I, Reserved | |
| Regulation Number / Panel: | 862.1680 / Clinical Chemistry |
- Predicate Device: EiAsvFreeTestosterone EIA 3. CompanyName: Diagnostic Biochem Canada, Inc. 510(k)Number: K030730
- A. TestPrinciple:
Monobind Inc. Free Testosterone test system uses a competitive enzyme immunoassay. The essential reagents required for a solid phase enzyme immunoassay include immobilized antibody, enzyme-antigen conjugate and native antigen. Upon mixing immobilized antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of insolubilized binding sites. After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an be ascertained. The serum calibrators are prepared in human serum matrix. The enzyme-antigen conjugate is labelled with horseradish peroxidase (HRP) and the substrate reagent contains tetramethylbenzidine (TMB), a blue color is produced. The reaction is stopped with addition of an acid and a yellow color is developed. The plate is read in a microtiter plate reader at 450nm.
-
B. KitDescription:
The kit consists of seven (7) vials of serum reference calibrators for Free Testosterone with two (2) controls (one low and one high); one (1) vial of Testosterone (Analog)-horseradish peroxidase (HRP) conjugate in a protein stabilizing matrix; one 96-well testosterone antibody-coated microplate; one (1) vial of concentrated wash solution; two (2) vials for tetramethy(benzidine (TMB) substrate solution preparation; and one (1) vial of stop reaction solution. -
C. Indications for Use:
The Free Testosterone AccuBind® ELISA Test System is an Enzyme Immunoassay (EIA) for the quantitative measurement of free testosterone in human serum. Measurement of free testosterone is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, impotence in males and in females; hirsutism (excessive hair) and virilization (masculinization)due to tumors, polycystic ovaries and adrogenital syndromes.
4
Comparison with Predicate (EiAsy Free Testosterone EIA):
Similarities and Differences
| Predicate | Monobind | |
|---|---|---|
| Intended Use | The direct quantitative | |
| determination of Free | ||
| Testosterone byenzyme | ||
| immunoassay in human serum | Same | |
| Antibody | Utilizes a highly specific rabbit | |
| polyclonal antibody at a low | ||
| binding capacity | Same | |
| Detection Method | Microplate colorimetricreader | Same |
| Test Principle | Competitive Enzyme | |
| Immunoassay | Same | |
| Sample Type | Human Serum | Same |
| Key Reagents | ||
| Calibrators | Six (6) vials containing | |
| testosterone in human serum | ||
| with preservative | Seven (7) vials containing | |
| testosterone in human serum with | ||
| preservative | ||
| Control | Two (2) vials containing | |
| testosterone in human serum | Three (3) vials containing | |
| testosterone in human serum | ||
| Calibrator/Control Matrix | Human Serum | Same |
| HRP conjugate | Testosterone-HRP conjugate | |
| in buffer | Same | |
| Wash Buffer Concentrate | Concentrated (10x) buffer with | |
| preservatives | Same | |
| TMB Substrate | One vial containing | |
| tetramethylbenzidine and | ||
| hydrogen peroxide in buffer | Two (2) vials: one containing | |
| tetramethylbenzidine, one | ||
| containing hydrogenperoxide | ||
| Microplate | Antibody coated plate | Same |
| Specimen treatment | Direct system; no specimen | |
| pretreatmentnecessary | Same | |
| Measuring range | 0.018-60pg/ml | 0.11-60pg/ml |
| Expected Range of values | ||
| (pg/ml) | Males / 20-39: 9.1-32.2 | |
| Males / 40-59: 5.7-30.7 | ||
| Males / ≥60: 5.9-27.0 | ||
| Females / 20-39: 0.1-6.3 | ||
| Females / 40-59: 0.3-5.0 | ||
| Females / ≥60: 0.5-3.9 | Males / 20-39: 9.2-34.6 | |
| Males / 40-59: 6.1-30.3 | ||
| Males / ≥60: 6.1-27.9 | ||
| Females / 20-39: 0.2-6.1 | ||
| Females / 40-59: 0.3-4.4 | ||
| Females / ≥60: 0.5-3.4 |
TestSummary
-
- AnalyticalPerformance
- Precision a.
This study was conducted during 20 days of testing. The human serum and control samples were tested in duplicate, two times per day for a total of 80 measurements per sample. Three (3) different reagent lots, three (3) serum pools, and three (3) controls were used for the study (low, medium, and high concentration). The results of a representative lot are shown below:
5
| Lot 1
| N=32 | Mean (pg/ml) | Within-Run | Total | ||
|---|---|---|---|---|---|
| SD | CV | SD | CV | ||
| Control 1 | 2.51 | 0.09 | 3.7% | 0.20 | 7.8% |
| Control 2 | 10.98 | 0.40 | 3.6% | 0.96 | 8.7% |
| Control 3 | 22.72 | 0.83 | 3.6% | 2.18 | 9.6% |
| Serum 1 | 0.98 | 0.06 | 5.9% | 0.12 | 12.4% |
| Serum 2 | 4.53 | 0.26 | 5.7% | 0.36 | 8.0% |
| Serum 3 | 53.62 | 4.24 | 7.9% | 4.32 | 8.1% |
The results of the combined lot precision are shown below:
| | Mean
Value
(pg/ml) | Within-Run Precision | | Within-Kit Precision | | Total Precision (n=80) | |
|-----------|--------------------------|----------------------|------|----------------------|------|------------------------|------|
| | | SD | CV% | SD | CV% | SD | CV% |
| Control 1 | 2.48 | 0.11 | 4.57 | 0.20 | 8.20 | 0.21 | 8.51 |
| Control 2 | 11.04 | 0.47 | 4.23 | 0.84 | 2.60 | 0.87 | 8.00 |
| Control 3 | 23.24 | 1.00 | 4.31 | 1.80 | 7.73 | 1.83 | 7.95 |
| Patient 1 | 0.97 | 0.05 | 4.88 | 0.09 | 9.14 | 0.08 | 9.43 |
| Patient 2 | 4.62 | 0.23 | 4.88 | 0.32 | 6.89 | 0.33 | 7.20 |
| Patient 3 | 54.66 | 3.25 | 5.95 | 3.92 | 7.17 | 4.13 | 7.55 |
Linearity b.
Sample preparations of 11 concentrations were prepared (0.10-64.91 pg/mL) and assayed per CLSI EP06-A guidance, Evaluation of the Linearity of Quantitative Measurement Procedures. The linear regression obtained is as follows: y=1.0149x-0.6028, R =0.9888
- c. Recovery
A study was performed to evaluate the recovery of the test system. Five serum samples containing different levels of endogenous testosterone were spiked with known concentrations of testosterone throughout the measuring range. The samples were measured in replicates of three and the average concentration was compared against the expected value. The recovery results are summarized below:
| Sample | Endogenous Concentration
(pg/ml) | Average % Recovery |
|-------------------|-------------------------------------|--------------------|
| Patient Sample #1 | 0.57 | 100.2% |
| Patient Sample #2 | 0.24 | 102.4% |
| Patient Sample #3 | 5.65 | 98.7% |
| Patient Sample #4 | 0.91 | 104.0% |
| Patient Sample #5 | 0.05 | 105.2% |
Image /page/5/Picture/9 description: The image shows the logo for Monobind Inc. The logo also includes the text "ISO 13485 & ISO 9001 Certified Company". There are also four small icons above the text. The icons are a magnifying glass, a microscope, a box, and an organizational chart.
6
-
d. ReagentStability/SampleStability
Real time stability studies are conducted to determine the reagent and kit shelf life (expiration date). Expiration date of the Monobind Free Testosterone AccuBind® ELISA Test System is determined by results of shelf studies and is based on the reagent that has the shorter assigned expirationdate. -
- The long term stability for kit reagents stored at 2-8 ℃ is 2 years from the manufacturingdate.
-
Open vial, Free Testosterone Calibrator and controls, Free Testosterone Enzyme 2. Reagentstabilitydetermination
| Condition | Stability | StorageTemperature |
|---|---|---|
| Open Kit Stability | 61 days | 2-8 °C |
| FreeTestosteroneCalibrators | 61 days | 2-8 °C |
| FreeTestosteroneControls | 61 days | 2-8 °C |
| Free Testo Enzyme Reagent | 61 days | 2-8 °C |
| TMB Substrate(A&B) | 61 days | 2-8 °C |
| Antibody Coated Plate | 61 days | 2-8 °C |
SampleStability
| Condition | Stability | StorageTemperature |
|---|---|---|
| Serum Sample | 61 days | 2-8°C |
| Frozen Serum Sample | 31 days | -20°C |
- Expected Reference Values e.
The reference range was established according to literature and verified utilizing 261 male and female serum samples. The reference range was calculated using CLSI C28-A3 as a guide. The following table indicates the summary of the results.
| Population | N | Reference Range (pg/ml) |
|---|---|---|
| Male / 20-39 | 45 | 9.2-34.6 |
| Male / 40-59 | 43 | 6.1-30.3 |
| Male / ≥60 | 43 | 6.1-27.9 |
| Female/20-39 | 44 | 0.2-6.1 |
| Female / 40-59 | 42 | 0.3-4.4 |
| Female / ≥60 | 44 | 0.5-3.4 |
- f. DetectionLimits
The LOB (limit of the blank), the LOD (limit of detection) and the LOQ (limit of quantitation) were determined in accordance with CLSI EP 17-A guideline, Protocols for Determination of Limits of Detection).
| Limit of the Blank (LoB) | Limit of Detection (LoD) | Limit of Quantitation (LoQ) |
|---|---|---|
| 0.0295pg/ml | 0.0519pg/ml | 0.0519pg/ml |
7
Diagnostic Products The World Resource for
g. CrossReactivity
Cross reactivity was determined by testing those compounds most likely to interfere with the Monobind Free Testosterone ELISA Test System. The specificity of the assay was determined in accordance with CLSI EP07-A2. Cross-reactivity was determined using the following equation: observed value - unspiked value/ concentration of cross-reactant x100%. Significant cross reactivity is defined as > 10% difference. The results of the cross-reactivity study are as follows.
| Sample | Conc.
(ng/ml) | Male Serum
Spiked Samples | | Blank Serum
Spiked Samples | |
|-------------------------------|------------------|------------------------------|---------------------|-------------------------------|---------------------|
| | | Conc
(pg/ml) | Cross
Reactivity | Conc.
(pg/ml) | Cross
Reactivity |
| Base Pool | 0 | 7.408 | - | 0 | - |
| 11-Deoxycortisol | 1000 | 7.269 | 0.000% | 0.000 | ND |
| 11-KetoTestosterone | 10 | 72.139 | 0.647% | 51.855 | 0.519% |
| 11β-Hydroxytestosterone | 100 | 72.815 | 0.065% | 54.000 | 0.054% |
| 17a-ethynyl estradiol | 1000 | 7.351 | 0.000% | 0.000 | ND |
| 17α-Estradiol | 1000 | 7.282 | 0.000% | 0.153 | 0.000% |
| 17β-Estradiol | 100 | 7.363 | 0.000% | 0.000 | ND |
| 17-Hydroxypregnenolone | 1000 | 7.35 | 0.000% | 0.000 | ND |
| 17-Hydroxprogesterone | 10 | 7.969 | 0.000% | 1.012 | 0.000% |
| 3-EstriolGluc | 1000 | 7.825 | 0.000% | 0.000 | ND |
| 3-EstriolSul | 1000 | 11.729 | 0.000% | 0.000 | ND |
| 3β-Androstanediol | 500 | 7.917 | 0.000% | 0.000 | ND |
| 5a-Dihydrotestosterone | 100 | 60.975 | 0.054% | 42.382 | 0.042% |
| Aldosterone | 8000 | 12.80 | 0.000% | 4.919 | 0.000% |
| AmitriptylHCI | 1000 | 7.301 | 0.000% | 0.000 | ND |
| Androsterone | 1000 | 8.061 | 0.000% | 0.000 | ND |
| Andronstenedione | 1000 | 50.552 | 0.004% | 19.248 | 0.002% |
| Clomiphene Citrate | 1000 | 7.263 | 0.000% | 0.000 | ND |
| Corticosterone | 1000 | 10.099 | 0.000% | 0.777 | 0.000% |
| Cortisone | 1000 | 9.90 | 0.000% | 0.478 | 0.000% |
| Cortisol | 1000 | 7.316 | 0.000% | 0.298 | 0.000% |
| Cyproteroneacetate | 1000 | 10.70 | 0.000% | 0.000 | ND |
| D-5-Androstene-3β,17β-diol | 1000 | 7.782 | 0.000% | 0.000 | ND |
| Danazol | 1000 | 12.30 | 0.000% | 0.000 | ND |
| DHEA | 100000 | 7.311 | 0.000% | 7.457 | 0.000% |
| DHEA-S | 1000 | 7.45 | 0.000% | 0.238 | 0.000% |
| Desogestrel | 100 | 7.436 | 0.000% | 0.000 | ND |
| Dexamethasone | 1000 | 7.381 | 0.000% | 0.000 | ND |
| Epistestosterone | 1000 | 21.612 | 0.001% | 8.215 | 0.001% |
| Estriol | 1000 | 7.368 | 0.000% | 0.122 | 0.000% |
| Estrone | 1000 | 7.679 | 0.000% | 0.036 | 0.000% |
| Ethisterone | 1000 | 8.597 | 0.000% | 0.003 | 0.000% |
| Sample | Conc.
(ng/ml) | Conc
(pg/ml) | Cross
Reactivity | Conc.
(pg/ml) | Cross
Reactivity |
| Ethynodiol | 1000 | 8.042 | 0.000% | 0.114 | 0.000% |
| Ethynodioldiacetate | 50 | 7.563 | 0.000% | 0.000 | ND |
| Flunisolide | 1000 | 7.456 | 0.000% | 0.000 | ND |
| Fluoxymesterone | 1000 | 7.450 | 0.000% | 0.000 | ND |
| Lynestrol | 1000 | 7.395 | 0.000% | 0.000 | ND |
| Medoxyprogesterone
acetate | 1000 | 7.426 | 0.000% | 0.000 | ND |
| Methyl Testosterone | 100 | 7.163 | 0.000% | 0.000 | ND |
| Mestranol | 1000 | 7.338 | 0.000% | 0.000 | ND |
| Norethindrone | 50 | 7.541 | 0.000% | 0.000 | ND |
| Norethinodroneacetate | 50 | 7.428 | 0.000% | 0.000 | ND |
| Norgestimate | 1000 | 7.478 | 0.000% | 0.000 | ND |
| Norgestrel (Levonorgestrel) | 50 | 7.463 | 0.000% | 0.000 | ND |
| Norethynodrel | 50 | 7.544 | 0.000% | 0.000 | ND |
| Oxymetholone | 100 | 7.401 | 0.000% | 0.000 | ND |
| Prednisolone | 1000 | 7.828 | 0.000% | 0.000 | ND |
| Prednisone | 800 | 10.442 | 0.000% | 0.966 | 0.000% |
| Progesterone | 1000 | 11.025 | 0.000% | 0.248 | 0.000% |
| Salbutamol | 1000 | 8.026 | 0.000% | 0.000 | ND |
| Spironolactone | 1000 | 7.310 | 0.000% | 0.112 | 0.000% |
| Stanozolol | 1000 | 7.442 | 0.000% | 0.081 | 0.000% |
| Testosteroneenanthate | 100 | 7.304 | 0.000% | 0.044 | 0.000% |
| Testosterone SO4 | 1000 | 75.970 | 0.004% | 28.182 | 0.003% |
| Testosterone Propionate | 1000 | 9.589 | 0.000% | 1.008 | 0.000% |
| Triamcinolone | 50 | 7.544 | 0.000% | 0.043 | 0.000% |
Image /page/7/Picture/5 description: The image shows the Monobind Inc. logo, which includes a magnifying glass, a microscope, a box, and a flowchart. The text "Monobind Inc." is located below the microscope. The text "ISO 13485 & ISO 9001 Certified Company" is located below the logo. The image is in a light blue color.
8
The World Resource for Diagnostic Products
An additional study was performed to evaluate the cross-reactivity effects of testosterone cypionate and testosterone undecanoate. Aliquots from pool of human serum with a free testosterone concentration of 38.4 pg/mL were spiked with 12 ng/mL of testosterone cypionate and testosterone undecanoate. Cross-reactivity was determined using the following equation: observed value - unspiked value/ concentration of cross-reactant x100%. Significant crossreactivity is defined as > 10% difference. The results are summarized in the chart below:
| Sample | Conc.
(ng/ml) | Conc.
(pg/ml) | Cross
Reactivity | Conc.
(pg/ml) | Cross
Reactivity |
|--------------------------|------------------|------------------|---------------------|------------------|---------------------|
| Testosterone Cypionate | 12 | 38.685 | 0.002% | 0.021 | 0.000% |
| Testosterone Undecanoate | 12 | 38.262 | -0.001% | 0.015 | -0.001% |
9
Method Comparison Studies 3.
Tests were conducted for comparison between the Free Testosterone ELISA Test System and the predicate assay, EiAsy Free Testosterone EIA. The free testosterone concentrations of 137 samples ranging from 0.11-59.63 pg/ml were compared. Comparison of the Monobind Free Testosterone AccuBind® ELISA Test System (new device) and the DBC EiAsy Free Testosterone EIA (predicate) show the following results:
| Method | Least Square Regression
Analysis | CorrelationCoefficient |
|-----------------|-------------------------------------|------------------------|
| This Method (y) | $y= 1.017x - 0.244$ | 0.997 |
| Reference(x) | | |
Interferences 4.
Using CLSI-A2 Interference Testing in Clinical Chemistry as a guide, potential interferents were tested utilizing charcoal-stripped human serum spiked with known concentrations of interferent.
The following results of % binding values even at higher than normal interferent levels indicate that there is no significant binding of the free testosterone-HRP conjugate.
| Substance | Highest concentration at which no significant
interference was observed |
|-----------------------|----------------------------------------------------------------------------|
| Acetaminophen | 20 mg/dl |
| Acetylcysteine | 150mg/dl |
| Ascorbic Acid | 6 mg/dl |
| Bilirubin Conjugated | 15 mg/dl |
| BilirubinUnconjugated | 20 mg/dl |
| Biotin | 100 ng/ml |
| Caffeine | 6 mg/dl |
| Cholesterol | 503mg/dl |
| Creatine | 30 mg/dl |
| Dextran | 5000 mg/dl |
| Digoxin | 6.1 ng/ml |
| Doxycycline | 50 mg/L |
| Erythromycin | 6 mg/dl |
| Gentamicin | 1 mg/dl |
| HAMA | 440 ng/ml |
| Heparin | 3 U/ml |
| Hemoglobin | 500mg/dl |
| Human Serum Albumin | 2.5 g/dl |
| Ibuprofen | 50 mg/dl |
| Immunoglobulin G | 4 g/dl |
| Levodopa | 20 mg/L |
| Lidocaine | 1.2mg/dl |
| Lipemia(glycerides) | 1000 mg/dl |
10
| Substance | Highest concentration at which no significant
interference was observed |
|-------------------|----------------------------------------------------------------------------|
| Methyldopa | 20 mg/L |
| Nicotine | 0.1 mg/dl |
| Phenobarbital | 15 mg/dl |
| Protein:Total | 10.5 g/dl |
| Rheumatoid Factor | 1110 IU/ml |
| Salicylic Acid | 60 mg/dl |
| SHBG | 200 µg/ml |
| Triglycerides | 900 mg/dl |
| Urea | 500mg/dl |
ConcludingStatement:
Taken together, the performance characteristics, comparison studies with a predicate device and acceptable statistical performance studies in this 510(k) Class I, reserved submission demonstrates that the Monobind Free Testosterone AccuBind® ELISA Test System is safe and effective for its intended use and is substantially equivalent to the predicate device.
Image /page/10/Picture/3 description: The image shows the Monobind Inc. logo, which includes a magnifying glass, a microscope, a box, and an organizational chart. Below the logo is the text "Monobind Inc." followed by "ISO 13485 & ISO 9001 Certified Company". The text indicates that Monobind Inc. is certified under ISO 13485 and ISO 9001 standards.